InvestorsHub Logo
Followers 261
Posts 19732
Boards Moderated 0
Alias Born 10/03/2004

Re: bunky post# 57528

Thursday, 03/27/2014 5:26:02 PM

Thursday, March 27, 2014 5:26:02 PM

Post# of 403047
I really prefer not to predict time lines, especially based on best case scenario. That said, If K has a DLT in Cohort 8, and MTD becomes 165 mg/m2, then Cohort 9 is the final one and end of trial is 6 months after finish of Cohort 9. Add it all up and K finishes in December to February.

B goes until September (I already said I thought it would finish earlier given the region and people), then the Phase 2b report can be ready before December and a license, if a license is desired, could be finalized this time 2015, if not earlier. Phase 3 will take 6 months after the end of data collection, minimal.

P is short and sweet. Confirmation of conversion to Abacavir will be in 45 to 60 days and Phase 2/3 can begin as soon as the FDA approves it. I agree with Gov, Leo et al probably have it already set up and ready to go following FDA clearance.

The market works 6 months in advance, so we should see positive movement as soon as biopharma sector reverses.

Sadly, I finally found Waldo in a picture.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News